Reuther T, Schuster T, Mende U, Kubler A. Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients—a report of a thirty year retrospective review. Int J Oral Maxillofac Surg 2003; 32:289–95.
Sciubba JJ, Goldenberg D. Oral complications of radiotherapy. The Lancet Ocology. 2006; 7:175-83.
Marx RE. Osteoradionecrosis. A new concept in its pathophysiology, J Oral Maxillofac Surg. 1983; 41:283–88.
Peleg M, Lopez EA. The treatment of osteoradionecrosis of the mandible: the case for hyperbaric oxygen and bone graft reconstruction. J Oral Maxillofac Surg 2006;64:956–60.
Koch BB, Karnell LH, Hoffman HT, Apostolakis LW, Robinson RA, Zhen W, Menck HR. National cancer database report on chondrosarcoma of the head and neck. Head Neck. 2000; 22:408-25.
Anil S, Beena VT, Lal PM, Varghese BJ. Chondrosarcoma of the maxilla. Case report. Aust Dent J. 1998; 43:172-74.
Hayt MW, Becker L, Katz DS. Chondrosarcoma of the maxilla: panoramic radiographic and computed tomographic with multiplanar reconstruction findings. Dentomaxillofac Radiol. 1998; 27:113-16.
Bennett JH, Thomas G, Evans AW, Speight PM. Osteosarcoma of the jaws: a 30-year retrospective review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90:323-32.
Oda D, Bavisotto LM, Schmidt RA, McNutt M, Bruckner JD, Conrad EU 3rd, Weymuller EA Jr. Head and neck osteosarcoma at the University of Washington. Head Neck 1997; 9:513-23.
Slootweg PJ, Muller H. Osteosarcoma of the jaw bones. Analysis of 18 cases. J Maxillofac Surg 1985; 13:158-166. A.
Hirshberg A, Buchner A. Metastatic tumours to the oral region. An overview. Oral Oncol. 1995; 31:355–60.
Ivan der Waal, RIF, Buter, J. Oral metastases: report of 24 cases. Br J Oral Maxillofac Surg. 2003; 41:3-6.
Uhler IV, Fahs GR, Dolan LA. Metastasis of cervical carcinoma to the mandible: report of a case. J Am Dent Assoc. 1972; 85:363-64.
Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, Diaz JM, Scully C. Jaw osteonecrosis associated with bisphosphonates: multiple exposure area and its relation to teeth extractions. Study of 20 cases. Oral Oncol. 2006; 42:327-29.
Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully C. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. Oral Pathol Med 2005; 34:120-23.
Blomen LJMJ. History of the bisphosphonates: discovery and history of the non medical uses of bisphosphonates. In: O.L.M. Bijvoet, H.A. Fleisch, R.E. Canfield and R.G.G. Russell, Editors, Bisphosphonates on Bones, Elsevier, Amsterdam 1995; 111–24.
Eyres KS, Marshall P, McCloskey E, Douglas DL, Kanis JA. Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate). Drug Saf. 1992; 7:162-5.
Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350;1189-99.
Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, Pini Prato G. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J. Clinical Periodontology. 2005; 32:1123-28.
Hellstein JW, Marek CL. Biphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg. 2005; 63:682-9.
Marx RE, letter. Pamidronate (Aredia) and zoledronate (Zometa) induced avasculkar necrosis of the jaws; a growing epidemic. J Oral Maxillo Surg 2003; 61:1115-17.
Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and Treatment. J Oral Maxillofac Surg 2005; 63:1567-75.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62:527-34.
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endo Metab 2005; 90:1294-1301.
Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 2005; 66:658-60.
Ott SM, Editorial. Long-term safety of bisphosphonates. J Clin Endo Metab 2005; 90:1897-99.
Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 16;144:735-61.
Durie BGM, Katz M, Crowley J. Zometa and osteonecrosis of the jaws; a new update. NEJM 2005; 353:99-102.
Purcell PM, Boyd IW. Biphosphonates and osteonecrosis of the jaw. MJA 2005; 182:417-8.
Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005; 23:8580-7.
Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA. Expert panel recommendations: Dental management of patients on oral bisphosphonate therapy. Report of the council on scientific affairs. American Dental Association, June, 2006. http://www.implantate.com/_media/pdf/osteonecrosis_recommendations.pdf.
